SCHEMBL4915495

SCHEMBL4915495

CCN1Cc2nc3c(-c4ccc(F)c(OC)c4)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 5/20 0.41
▸ CD274 Q9NZQ7 1/20 0.38
▸ ABCG2 Q9UNQ0 3/20 0.37
▸ PIK3CG P48736 3/20 0.36
▸ GABRA1 P14867 2/20 0.35
▸ GABRG2 P18507 2/20 0.35
▸ GABRB3 P28472 2/20 0.35
▸ GABRA5 P31644 2/20 0.35
▸ GABRA3 P34903 2/20 0.35
▸ GABRA2 P47869 1/20 0.35
▸ SCN9A Q15858 2/20 0.35
▸ SIK2 Q9H0K1 2/20 0.35
▸ PDE6C P51160 1/20 0.34
▸ ABCC1 P33527 1/20 0.34
▸ METAP2 P50579 1/20 0.34
▸ SYK P43405 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917169 0.93 PDE5A (0.42) PDE5ACD274GABRA1GABRG2GABRB3
SCHEMBL2656333 0.92 PDE5A (0.44) PDE5APIK3CGSIK2PDE6C
SCHEMBL4919706 0.86 GABRA1 (0.49) PDE5AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2655510 0.86 PDE5A (0.41) PDE5AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2661396 0.85 PDE5A (0.43) PDE5AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2657124 0.84 PDE5A (0.41) PDE5APIK3CGGABRA1GABRG2GABRB3
SCHEMBL2655165 0.84 PDE5A (0.43) PDE5AGABRA1GABRG2GABRB3GABRA5
SCHEMBL4924170 0.84 TP53 (0.42) PDE5APIK3CGPDE4D
SCHEMBL2661952 0.84 PDE5A (0.40) PDE5AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2661141 0.84 PDE5A (0.40) PDE5AGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF PDE5A 742/4885CD274 2918/4885ABCG2 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback